[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Meet Elizabeth Wagner, Acting Chief Operating Officer.
Elizabeth brings 18+ years of relationship-building across CROs, labs, consultants, and CDMOs to help startups move their pipelines forward. As former COO of Constant Therapeutics, she led the company to three Phase 2 assets and advanced a peptide oral formulation program through GMP production. Earlier: Corporate Development at Cubist Pharmaceuticals, Portfolio Planning at Genentech, and Clinical Research at Genzyme.
She's the person making sure Glafabra's operational pieces — manufacturing relationships, trial logistics, vendor management — actually connect.
For the operators here: what's the hardest lesson you've learned about scaling a biotech's operations from a handful of people?
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0